サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1762314

前立腺がんバイオマーカー市場、規模、シェア、産業分析レポート：タイプ別、用途別、最終用途別、地域別、2025年～2034年の市場予測

Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
前立腺がんバイオマーカー市場、規模、シェア、産業分析レポート：タイプ別、用途別、最終用途別、地域別、2025年～2034年の市場予測
出版日: 2025年05月01日
発行: Polaris Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、前立腺がんバイオマーカー市場規模は2034年までに155億8,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

前立腺がんバイオマーカーは、前立腺がんの存在、病期、進行を特定するのに役立つ体液や組織由来の分子指標です。ゲノミクス、プロテオミクス、メタボロミクスにおけるAIなどのマルチオミクスアプローチの統合により、診断精度の向上と疾患層別化が進み、市場の需要をさらに押し上げています。これらの幅広いプロファイリング技術は、より高い感度と特異性を持つ新規バイオマーカーの発見を可能にし、より正確な患者分類とオーダーメイドの治療戦略をサポートします。マルチオミクス主導型バイオマーカープラットフォームの採用は、個別化されたがん治療への注目が高まるにつれて、臨床および研究の場でますます中心的な存在になりつつあります。

非侵襲的で低侵襲な診断技術の進歩が市場開拓を後押ししています。リキッドバイオプシーは、血液または尿サンプルを用いて前立腺がんを検出・モニタリングする能力で支持を集めており、従来の組織生検に代わる、より安全で便利な方法を提供しています。これらの方法は、患者のコンプライアンスを改善し、リアルタイムの疾患モニタリングと治療法の調整を可能にします。ヘルスケアシステムが早期発見と侵襲性の低い診断を優先するにつれて、このような革新的技術に対する需要は増加の一途をたどっており、前立腺がん管理の変革における先進バイオマーカー技術の役割が強化されています。

前立腺がんバイオマーカー市場レポート・ハイライト

タイプ別では、タンパク質バイオマーカー分野が2024年に最大の市場シェアを占め、その広範な臨床応用と複数の疾患管理フェーズにわたる確立された検証が支持されました。

用途別では、個別化治療アプローチと精密治療の導入が拡大していることから、コンパニオン診断分野が最も急速に拡大すると予測されています。

2024年には、北米が前立腺がんバイオマーカー市場で最大の売上シェアを維持したが、これは洗練されたヘルスケアシステム、疾患に対する意識の高まり、診断薬・バイオ医薬品企業の集積によるものです。

アジア太平洋市場は、ヘルスケア知識の向上、診断能力の市場開拓、新興国におけるがん罹患率の増加に牽引され、予測期間中に最も速い市場成長を達成すると予測されています。

世界の主な市場プレイヤーとしては、Arquer Diagnostics社、Beckman Coulter社、Bio-Techne社、DiaCarta社、Exact Sciences Corporation社、ExoDx社、Genomic Health社、GenPath Oncology社、MDxHealth社、Myriad Genetics社、Nucleix社、OPKO Health社、Proteomedix社、Veracyte社などが挙げられます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の前立腺がんバイオマーカー市場の洞察

  • 市場スナップショット
  • 前立腺がんバイオマーカー市場力学
    • 促進要因と機会
      • 前立腺がんの罹患率の上昇と人口の高齢化
      • バイオマーカー技術の進歩
    • 抑制要因と課題
      • バイオマーカーの開発と試験にかかる高コスト
    • 世論とプライバシーに関する判例
  • PESTEL分析
  • 前立腺がんバイオマーカー市場動向
  • バリューチェーン分析

第5章 世界の前立腺がんバイオマーカー市場：タイプ別

  • 主な調査結果
  • イントロダクション
  • 遺伝子バイオマーカー
  • タンパク質バイオマーカー
  • 細胞ベースのバイオマーカー
  • メタボロミクスバイオマーカー

第6章 世界の前立腺がんバイオマーカー市場：用途別

  • 主な調査結果
  • イントロダクション
  • スクリーニングと早期発見
  • 診断とリスク層別化
  • 予後と治療のモニタリング
  • コンパニオン診断

第7章 世界の前立腺がんバイオマーカー市場：最終用途別

  • 主な調査結果
  • イントロダクション
  • 病院および診断検査室
  • 学術研究機関
  • バイオ医薬品企業

第8章 世界の前立腺がんバイオマーカー市場：地域別

  • 主な調査結果
  • イントロダクション
    • 前立腺がんバイオマーカー市場分析：地域別、2020～2034年
  • 北米
    • 北米：タイプ別、2020～2034年
    • 北米：用途別、2020～2034年
    • 北米：最終用途別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：タイプ別、2020～2034年
    • 欧州：用途別、2020～2034年
    • 欧州：最終用途別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：タイプ別、2020～2034年
    • アジア太平洋地域：用途別、2020～2034年
    • アジア太平洋地域：最終用途別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：タイプ別、2020～2034年
    • 中東・アフリカ：用途別、2020～2034年
    • 中東・アフリカ：最終用途別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：タイプ別、2020-2034年
    • ラテンアメリカ：用途別、2020～2034年
    • ラテンアメリカ：最終用途別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AlterG, Inc.
  • Biodex Medical Systems, Inc.
  • Caremax Prostate Cancer Biomarker Ltd.
  • DJO Global
  • Drive DeVilbiss Healthcare
  • Ekso Bionics
  • GF Health Products, Inc.
  • Hocoma AG
  • Hospital Equipment Mfg. Co
  • Invacare Corporation
  • Maddak, Inc.
  • Ottobock
  • Patterson Medical（now Ability Dynamics）
  • Rifton Equipment
  • TheraBand（Performance Health）
図表

List of Tables:

  • Table 1 Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 2 Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 3 Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 4 North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 5 North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 6 North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 8 US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 9 US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 10 Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 12 Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 15 Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 16 UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 17 UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 18 UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 20 France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 21 France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 22 Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 24 Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 27 Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 28 Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 30 Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 34 Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 36 Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 44 China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 45 China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 46 India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 47 India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 48 India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 52 Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 54 Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 58 South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 60 South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 63 Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 73 UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 75 UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 76 Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 78 Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 79 South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 81 South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 85 Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 87 Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 88 Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 90 Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 91 Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 93 Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 94 Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 96 Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Prostate Cancer Biomarker Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Prostate Cancer Biomarker Market, by Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Application
  • Figure 9. Global Prostate Cancer Biomarker Market, by Application, 2024 & 2034 (USD Billion)
  • Figure 10. Market by End Use
  • Figure 11. Global Prostate Cancer Biomarker Market, by End Use, 2024 & 2034 (USD Billion)
目次
Product Code: PM5692

The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.

The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.

Prostate Cancer Biomarker Market Report Highlights

In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.

Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.

In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.

The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.

A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.

Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Genetic Biomarkers

Protein Biomarkers

Cell-based Biomarkers

Metabolomic Biomarkers

By Application Outlook (Revenue, USD Billion, 2020-2034)

Screening and Early Detection

Diagnosis and Risk Stratification

Prognosis and Treatment Monitoring

Companion Diagnostics

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Hospitals & Diagnostic Laboratories

Academic & Research Institutes

Biopharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Prostate Cancer Biomarker Market Insights

  • 4.1. Prostate Cancer Biomarker Market - Market Snapshot
  • 4.2. Prostate Cancer Biomarker Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Prevalence of Prostate Cancer and Aging Populations
      • 4.2.1.2. Advancements in Biomarker Technologies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Biomarker Development and Testing
    • 4.2.3. Public opinion and privacy legal precedents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Prostate Cancer Biomarker Market Trends
  • 4.6. Value Chain Analysis

5. Global Prostate Cancer Biomarker Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
  • 5.3. Genetic Biomarkers
    • 5.3.1. Global Prostate Cancer Biomarker Market, by Genetic Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.4. Protein Biomarkers
    • 5.4.1. Global Prostate Cancer Biomarker Market, by Protein Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.5. Cell-based Biomarkers
    • 5.5.1. Global Prostate Cancer Biomarker Market, by Cell-based Biomarkers, by Region, 2020-2034 (USD Billion)
  • 5.6. Metabolomic Biomarkers
    • 5.6.1. Global Prostate Cancer Biomarker Market, by Metabolomic Biomarkers, by Region, 2020-2034 (USD Billion)

6. Global Prostate Cancer Biomarker Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
  • 6.3. Screening and Early Detection
    • 6.3.1. Global Prostate Cancer Biomarker Market, by Screening and Early Detection, by Region, 2020-2034 (USD Billion)
  • 6.4. Diagnosis and Risk Stratification
    • 6.4.1. Global Prostate Cancer Biomarker Market, by Diagnosis and Risk Stratification, by Region, 2020-2034 (USD Billion)
  • 6.5. Prognosis and Treatment Monitoring
    • 6.5.1. Global Prostate Cancer Biomarker Market, by B-Arrestin Functional Assays, by Region, 2020-2034 (USD Billion)
  • 6.6. Companion Diagnostics
    • 6.6.1. Global Prostate Cancer Biomarker Market, by Companion Diagnostics, by Region, 2020-2034 (USD Billion)

7. Global Prostate Cancer Biomarker Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 7.3. Hospitals & Diagnostic Laboratories
    • 7.3.1. Global Prostate Cancer Biomarker Market, by Hospitals & Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
  • 7.4. Academic & Research Institutes
    • 7.4.1. Global Prostate Cancer Biomarker Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Global Prostate Cancer Biomarker Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)

8. Global Prostate Cancer Biomarker Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Prostate Cancer Biomarker Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Prostate Cancer Biomarker Market - North America
    • 8.3.1. North America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.3.3. North America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.4. Prostate Cancer Biomarker Market - US
      • 8.3.4.1. US: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.4.3. US: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.3.5. Prostate Cancer Biomarker Market - Canada
      • 8.3.5.1. Canada: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.4. Prostate Cancer Biomarker Market - Europe
    • 8.4.1. Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.4. Prostate Cancer Biomarker Market - UK
      • 8.4.4.1. UK: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.5. Prostate Cancer Biomarker Market - France
      • 8.4.5.1. France: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.6. Prostate Cancer Biomarker Market - Germany
      • 8.4.6.1. Germany: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.7. Prostate Cancer Biomarker Market - Italy
      • 8.4.7.1. Italy: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.8. Prostate Cancer Biomarker Market - Spain
      • 8.4.8.1. Spain: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.9. Prostate Cancer Biomarker Market - Netherlands
      • 8.4.9.1. Netherlands: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.10. Prostate Cancer Biomarker Market - Russia
      • 8.4.10.1. Russia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.4.11. Prostate Cancer Biomarker Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.5. Prostate Cancer Biomarker Market - Asia Pacific
    • 8.5.1. Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.4. Prostate Cancer Biomarker Market - China
      • 8.5.4.1. China: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.5. Prostate Cancer Biomarker Market - India
      • 8.5.5.1. India: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.6. Prostate Cancer Biomarker Market - Malaysia
      • 8.5.6.1. Malaysia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.7. Prostate Cancer Biomarker Market - Japan
      • 8.5.7.1. Japan: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.8. Prostate Cancer Biomarker Market - Indonesia
      • 8.5.8.1. Indonesia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.9. Prostate Cancer Biomarker Market - South Korea
      • 8.5.9.1. South Korea: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.10. Prostate Cancer Biomarker Market - Australia
      • 8.5.10.1. Australia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.5.11. Prostate Cancer Biomarker Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.6. Prostate Cancer Biomarker Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.4. Prostate Cancer Biomarker Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.5. Prostate Cancer Biomarker Market - UAE
      • 8.6.5.1. UAE: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.6. Prostate Cancer Biomarker Market - Israel
      • 8.6.6.1. Israel: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.7. Prostate Cancer Biomarker Market - South Africa
      • 8.6.7.1. South Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.6.8. Prostate Cancer Biomarker Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
  • 8.7. Prostate Cancer Biomarker Market - Latin America
    • 8.7.1. Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.4. Prostate Cancer Biomarker Market - Mexico
      • 8.7.4.1. Mexico: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.5. Prostate Cancer Biomarker Market - Brazil
      • 8.7.5.1. Brazil: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.6. Prostate Cancer Biomarker Market - Argentina
      • 8.7.6.1. Argentina: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)
    • 8.7.7. Prostate Cancer Biomarker Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Prostate Cancer Biomarker Market, by Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Prostate Cancer Biomarker Market, by Application, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Prostate Cancer Biomarker Market, by End Use, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AlterG, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Biodex Medical Systems, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Caremax Prostate Cancer Biomarker Ltd.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. DJO Global
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Drive DeVilbiss Healthcare
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Ekso Bionics
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GF Health Products, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Hocoma AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Hospital Equipment Mfg. Co
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Invacare Corporation
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Maddak, Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Ottobock
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Patterson Medical (now Ability Dynamics)
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Rifton Equipment
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
  • 10.15. TheraBand (Performance Health)
    • 10.15.1. Company Overview
    • 10.15.2. Financial Performance
    • 10.15.3. Product Benchmarking
    • 10.15.4. Recent Development